Increased risk of bone tumors after growth hormone treatment in childhood: A population-based cohort study in France.

ABSTRACT: The association between growth hormone (GH) treatment and cancer risk has not been thoroughly evaluated and there are questions about any increased risk of bone tumors. We examined cancer risk and especially bone tumor risk in a population-based cohort study of 6874 patients treated with recombinant GH in France for isolated GH deficiency, short stature associated with low birth weight or length or idiopathic short stature. Adult mortality and morbidity data obtained from national databases and from questionnaires. Case ascertainment completeness was estimated with capture-recapture methods. Standardized mortality and incidence ratios were calculated using national reference data. 111 875 person-years of observation were analyzed and patients were followed for an average of 17.4 ± 5.3 year

SUBMITTER: Poidvin A 

PROVIDER: S-EPMC6051149 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature